Hamish is an Operating Partner at SV Life Sciences Advisers, LLC (SVLS) and has acted as Interim CEO at X2-Pharma, Delenex Therapeutics and TopiVert Pharma and Chief Commercial Officer at ESBATech. He currently serves as a Director at Affinium, Delenex and VHsquared, in addition to TopiVert. Before joining SVLS, Hamish was CEO of Cambridge Antibody Technology (CAT). He has also held a number of senior R&D positions at AstraZeneca/Zeneca including Head of the Cardiovascular Therapy Area, Senior Vice-President Medical Research and he was a member of the R&D Leadership Team. Hamish started his industry career with Janssen, after working in clinical practice and research in the UK. He trained as a physician and holds MBBS and BSc (Hons) Pharmacology degrees from the University of London. He is a member of the UK Royal College of Physicians and a Fellow and past Board member of the Faculty of Pharmaceutical Medicine Hamish is an Operating Partner at SV Life Sciences Advisers, LLC (SVLS) and has acted as Interim CEO at X2-Pharma, Delenex Therapeutics and TopiVert Pharma and Chief Commercial Officer at ESBATech. He currently serves as a Director at Affinium, Delenex and VHsquared, in addition to TopiVert. Before joining SVLS, Hamish was CEO of Cambridge Antibody Technology (CAT). He has also held a number of senior R&D positions at AstraZeneca/Zeneca including Head of the Cardiovascular Therapy Area, Senior Vice-President Medical Research and he was a member of the R&D Leadership Team. Hamish started his industry career with Janssen, after working in clinical practice and research in the UK. He trained as a physician and holds MBBS and BSc (Hons) Pharmacology degrees from the University of London. He is a member of the UK Royal College of Physicians and a Fellow and past Board member of the Faculty of Pharmaceutical Medicine

fermentation